The Europe Lymphoma Therapeutics Market should witness market growth of 7.3% CAGR during the forecast period (2023-2029).
The expansion of the market is due to the rising incidence of non-Hodgkin lymphoma; this is one of the key elements driving the growth of the market. In addition, the expanding population of elderly people, who are more likely to suffer from conditions like these, is also contributing to the expansion of the market. Along these lines, the growing awareness among the general public regarding the various lymphoma diagnostic technologies and treatment options is also contributing to the market expansion.
Hospitals and other diagnostic facilities are utilizing cutting-edge tests and imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans, to accurately identify cancer cells and initiate therapy at the appropriate time. In addition, the discovery of novel immune checkpoint inhibitors and other technological breakthroughs are helping to expand the market. These inhibitors prevent proteins from covalently bonding with one another and boost the T-cells' ability to mount an effective immune response against cancer cells.
Germany today has a life expectancy that is more than twice as high as it had at the beginning of the 20th century. Right now, it's predicted that newborn boys will live 78 years and newborn girls 83 years. Demographic trends are reflected in the population's age distribution. Approximately 25% of the population in Germany is already 60 or older, and this percentage is projected to rise. With the growing old-age population in the region, the prevalence of lymphoma, especially non-Hodgkin lymphoma, is expected to increase, providing more growth opportunities for market expansion in Europe.
The Germany market dominated the Europe Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,655.3 million by 2029. The UK market is experiencing a CAGR of 6.4% during (2023-2029). Additionally, The France market would exhibit a CAGR of 8.2% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
The expansion of the market is due to the rising incidence of non-Hodgkin lymphoma; this is one of the key elements driving the growth of the market. In addition, the expanding population of elderly people, who are more likely to suffer from conditions like these, is also contributing to the expansion of the market. Along these lines, the growing awareness among the general public regarding the various lymphoma diagnostic technologies and treatment options is also contributing to the market expansion.
Hospitals and other diagnostic facilities are utilizing cutting-edge tests and imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans, to accurately identify cancer cells and initiate therapy at the appropriate time. In addition, the discovery of novel immune checkpoint inhibitors and other technological breakthroughs are helping to expand the market. These inhibitors prevent proteins from covalently bonding with one another and boost the T-cells' ability to mount an effective immune response against cancer cells.
Germany today has a life expectancy that is more than twice as high as it had at the beginning of the 20th century. Right now, it's predicted that newborn boys will live 78 years and newborn girls 83 years. Demographic trends are reflected in the population's age distribution. Approximately 25% of the population in Germany is already 60 or older, and this percentage is projected to rise. With the growing old-age population in the region, the prevalence of lymphoma, especially non-Hodgkin lymphoma, is expected to increase, providing more growth opportunities for market expansion in Europe.
The Germany market dominated the Europe Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,655.3 million by 2029. The UK market is experiencing a CAGR of 6.4% during (2023-2029). Additionally, The France market would exhibit a CAGR of 8.2% during (2023-2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
Scope of the Study
By Treatment Type
- Immune Therapy
- Target Therapy
- Chemotherapy
- Radiation Therapy
By Disease Type
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
By Route of Administration
- Injectable
- Oral Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F.Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Lymphoma Therapeutics Market, by Treatment Type
1.4.2 Europe Lymphoma Therapeutics Market, by Disease Type
1.4.3 Europe Lymphoma Therapeutics Market, by Route of Administration
1.4.4 Europe Lymphoma Therapeutics Market, by Distribution Channel
1.4.5 Europe Lymphoma Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Analyst's Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Europe Lymphoma Therapeutics Market by Treatment Type
4.1 Europe Immune Therapy Market by Country
4.2 Europe Target Therapy Market by Country
4.3 Europe Chemotherapy Market by Country
4.4 Europe Radiation Therapy Market by Country
Chapter 5. Europe Lymphoma Therapeutics Market by Disease Type
5.1 Europe Non-Hodgkin Lymphoma Market by Country
5.2 Europe Hodgkin Lymphoma Market by Country
Chapter 6. Europe Lymphoma Therapeutics Market by Route of Administration
6.1 Europe Injectable Market by Country
6.2 Europe Oral Route Market by Country
Chapter 7. Europe Lymphoma Therapeutics Market by Distribution Channel
7.1 Europe Hospital Pharmacies Market by Country
7.2 Europe Retail Pharmacies Market by Country
7.3 Europe Others Market by Country
Chapter 8. Europe Lymphoma Therapeutics Market by Country
8.1 Germany Lymphoma Therapeutics Market
8.1.1 Germany Lymphoma Therapeutics Market by Treatment Type
8.1.2 Germany Lymphoma Therapeutics Market by Disease Type
8.1.3 Germany Lymphoma Therapeutics Market by Route of Administration
8.1.4 Germany Lymphoma Therapeutics Market by Distribution Channel
8.2 UK Lymphoma Therapeutics Market
8.2.1 UK Lymphoma Therapeutics Market by Treatment Type
8.2.2 UK Lymphoma Therapeutics Market by Disease Type
8.2.3 UK Lymphoma Therapeutics Market by Route of Administration
8.2.4 UK Lymphoma Therapeutics Market by Distribution Channel
8.3 France Lymphoma Therapeutics Market
8.3.1 France Lymphoma Therapeutics Market by Treatment Type
8.3.2 France Lymphoma Therapeutics Market by Disease Type
8.3.3 France Lymphoma Therapeutics Market by Route of Administration
8.3.4 France Lymphoma Therapeutics Market by Distribution Channel
8.4 Russia Lymphoma Therapeutics Market
8.4.1 Russia Lymphoma Therapeutics Market by Treatment Type
8.4.2 Russia Lymphoma Therapeutics Market by Disease Type
8.4.3 Russia Lymphoma Therapeutics Market by Route of Administration
8.4.4 Russia Lymphoma Therapeutics Market by Distribution Channel
8.5 Spain Lymphoma Therapeutics Market
8.5.1 Spain Lymphoma Therapeutics Market by Treatment Type
8.5.2 Spain Lymphoma Therapeutics Market by Disease Type
8.5.3 Spain Lymphoma Therapeutics Market by Route of Administration
8.5.4 Spain Lymphoma Therapeutics Market by Distribution Channel
8.6 Italy Lymphoma Therapeutics Market
8.6.1 Italy Lymphoma Therapeutics Market by Treatment Type
8.6.2 Italy Lymphoma Therapeutics Market by Disease Type
8.6.3 Italy Lymphoma Therapeutics Market by Route of Administration
8.6.4 Italy Lymphoma Therapeutics Market by Distribution Channel
8.7 Rest of Europe Lymphoma Therapeutics Market
8.7.1 Rest of Europe Lymphoma Therapeutics Market by Treatment Type
8.7.2 Rest of Europe Lymphoma Therapeutics Market by Disease Type
8.7.3 Rest of Europe Lymphoma Therapeutics Market by Route of Administration
8.7.4 Rest of Europe Lymphoma Therapeutics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expenses
9.3.4 Recent strategies and developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.3.4.2 Acquisition and Mergers:
9.3.4.3 Approvals and Trials:
9.4 Bristol Myers Squibb Company
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Acquisition and Mergers:
9.4.5.2 Approvals and Trials:
9.5 Pfizer, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional & Segmental Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.5.5.2 Approvals and Trials:
9.6 AstraZeneca PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Acquisition and Mergers:
9.6.5.3 Approvals and Trials:
9.7 Teva Pharmaceutical Industries Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expenses
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Product Launches and Product Expansions:
9.8 Eli Lilly And Company
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Acquisition and Mergers:
9.8.5.2 Approvals and Trials:
9.9 Seagen, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals and Trials:
9.10. F. Hoffmann-La Roche Ltd.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
Companies Mentioned
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences, Inc.
- Seagen, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Eli Lilly And Company
Methodology
LOADING...
